{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:28:42Z","timestamp":1780669722948,"version":"3.54.1"},"posted":{"date-parts":[[2024,5,9]]},"group-title":"In Review","reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,3,18]]},"abstract":"<title>Abstract<\/title><p>Ductal carcinoma<italic>in situ<\/italic>(DCIS) constitutes an array of morphologically recognized intraductal neoplasms in the mammary ductal tree defined by an increased risk for subsequent invasive carcinomas at or near the site of biopsy detection. However, only 15-45% of untreated DCIS cases progress to invasive cancer, so understanding mechanisms that prevent progression is key to avoid overtreatment and provides a basis for alternative therapies and prevention. This study was designed to characterize the tumor microenvironment and molecular profile of high-risk DCIS that grew to a large size but remained as DCIS. All patients had DCIS lesions &gt;5cm in size with at least one additional high-risk feature: young age (&lt;45 years), high nuclear grade, hormone receptor negativity, HER2 positivity, the presence of comedonecrosis, or a palpable mass. The tumor immune microenvironment was characterized using multiplex immunofluorescence to identify immune cells and their spatial relationships within the ducts and stroma. Gene copy number analysis and whole exome DNA sequencing identified the mutational burden and driver mutations, and quantitative whole-transcriptome\/gene expression analyses were performed. There was no association between the percent of the DCIS genome characterized by copy number variants (CNAs) and recurrence events (DCIS or invasive). Mutations, especially missense mutations, in the breast cancer driver genes<italic>PIK3CA<\/italic>and<italic>TP53<\/italic>were common in this high-risk DCIS cohort (47% of evaluated lesions). Tumor infiltrating lymphocyte (TIL) density was higher in DCIS lesions with TP53 mutations (p=0.0079) compared to wildtype lesions, but not in lesions with<italic>PIK3CA<\/italic>mutations (p=0.44). Immune infiltrates were negatively associated with hormone receptor status and positively associated with HER2 expression. High levels of CD3+CD8- T cells were associated with good outcomes with respect to any subsequent recurrence (DCIS or invasive cancer), whereas high levels of CD3+Foxp3+ Treg cells were associated with poor outcomes. Spatial proximity analyses of immune cells and tumor cells demonstrated that close proximity of T cells with tumor cells was associated with good outcomes with respect to any recurrence as well as invasive recurrences. Interestingly, we found that myoepithelial continuity (distance between myoepithelial cells surrounding the involved ducts) was significantly lower in DCIS lesions compared to normal tissue (p=0.0002) or to atypical ductal hyperplasia (p=0.011). Gene set enrichment analysis identified several immune pathways associated with low myoepithelial continuity and a low myoepithelial continuity score was associated with better outcomes, suggesting that gaps in the myoepithelial layer may allow access\/interactions between immune infiltrates and tumor cells. Our study demonstrates the immune microenvironment of DCIS, in particular the spatial proximity of tumor cells and T cells, and myoepithelial continuity are important determinants for progression of disease.<\/p>","DOI":"10.21203\/rs.3.rs-4126092\/v1","type":"posted-content","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T20:48:06Z","timestamp":1715287686000},"source":"Crossref","is-referenced-by-count":4,"title":["Tumor microenvironmental determinants of high-risk DCIS progression"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3117-9202","authenticated-orcid":false,"given":"Alexander","family":"Borowsky","sequence":"first","affiliation":[{"name":"UC Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Glencer","sequence":"additional","affiliation":[{"name":"UCSF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-6891","authenticated-orcid":false,"given":"Kirithiga","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"UCSF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schindler","sequence":"additional","affiliation":[{"name":"UCSF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parchi","family":"Ghule","sequence":"additional","affiliation":[{"name":"Univ Vermont Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Lee","sequence":"additional","affiliation":[{"name":"U Vermot"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Nachmanson","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Officer","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Harismendy","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-6822","authenticated-orcid":false,"given":"Janet","family":"Stein","sequence":"additional","affiliation":[{"name":"University of Vermont College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Stein","sequence":"additional","affiliation":[{"name":"University of Vermont Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Evans","sequence":"additional","affiliation":[{"name":"U Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Weaver","sequence":"additional","affiliation":[{"name":"U Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[{"name":"UCSF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-0035","authenticated-orcid":false,"given":"Gillian","family":"Hirst","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3788-9240","authenticated-orcid":false,"given":"Michael","family":"Campbell","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[{"name":"UCSF"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y","article-title":"Intraductal carcinoma of the breast: follow-up after biopsy only","volume":"49","author":"Page DL","year":"1982","unstructured":"Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49:751\u2013758","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5858\/arpa.2012-0078-RA","article-title":"Ductal carcinoma in situ of the breast: current concepts and future directions","volume":"137","author":"Siziopikou KP","year":"2013","unstructured":"Siziopikou KP (2013) Ductal carcinoma in situ of the breast: current concepts and future directions. Arch Pathol Lab Med 137:462\u2013466","journal-title":"Arch Pathol Lab Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(13)70598-9","article-title":"Addressing overdiagnosis and overtreatment in cancer: a prescription for change","volume":"15","author":"Esserman LJ","year":"2014","unstructured":"Esserman LJ et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234\u2013242","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cncr.20979","article-title":"Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses\u2019 Health Study","volume":"103","author":"Collins LC","year":"2005","unstructured":"Collins LC et al (2005) Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses\u2019 Health Study. Cancer 103:1778\u20131784","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1186\/s12885-015-1904-7","article-title":"Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis","volume":"15","author":"Stuart KE","year":"2015","unstructured":"Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J (2015) Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer 15:890","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e2017124","DOI":"10.1001\/jamanetworkopen.2020.17124","article-title":"Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer","volume":"3","author":"Giannakeas V","year":"2020","unstructured":"Giannakeas V, Sopik V, Narod SA (2020) Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. JAMA Netw Open 3:e2017124","journal-title":"JAMA Netw Open"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnci\/djn013","article-title":"The sea of uncertainty surrounding ductal carcinoma in situ\u2013the price of screening mammography","volume":"100","author":"Welch HG","year":"2008","unstructured":"Welch HG, Woloshin S, Schwartz LM (2008) The sea of uncertainty surrounding ductal carcinoma in situ\u2013the price of screening mammography. J Natl Cancer Inst 100:228\u2013229","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.pathol.2019.07.005","article-title":"Ductal carcinoma in situ of breast: update 2019","volume":"51","author":"Badve SS","year":"2019","unstructured":"Badve SS, G\u00f6kmen-Polar Y (2019) Ductal carcinoma in situ of breast: update 2019. Pathology 51:563\u2013569","journal-title":"Pathology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","article-title":"A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone","volume":"152","author":"Rakovitch E","year":"2015","unstructured":"Rakovitch E et al (2015) A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152:389\u2013398","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/annonc\/mdv062","article-title":"Molecular phenotypes of DCIS predict overall and invasive recurrence","volume":"26","author":"Williams KE","year":"2015","unstructured":"Williams KE et al (2015) Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol 26:1019\u20131025","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1158\/1078-0432.CCR-07-4960","article-title":"Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study","volume":"14","author":"Iakovlev VV","year":"2008","unstructured":"Iakovlev VV et al (2008) Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clin Cancer Res 14:4446\u20134454","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"R87","DOI":"10.1186\/bcr2157","article-title":"Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma","volume":"10","author":"Castro NP","year":"2008","unstructured":"Castro NP et al (2008) Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 10:R87","journal-title":"Breast Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2017.12.007","article-title":"Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing","volume":"172","author":"Casasent AK","year":"2018","unstructured":"Casasent AK et al (2018) Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing. Cell 172:205\u2013217e12","journal-title":"Cell"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.18632\/oncotarget.3162","article-title":"Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer","volume":"6","author":"Kim SY","year":"2015","unstructured":"Kim SY et al (2015) Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget 6:7597\u20137607","journal-title":"Oncotarget"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","article-title":"Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast","volume":"161","author":"Campbell MJ","year":"2017","unstructured":"Campbell MJ et al (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17\u201328","journal-title":"Breast Cancer Res Treat"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-009-0654-0","article-title":"Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ","volume":"123","author":"Sharma M","year":"2010","unstructured":"Sharma M et al (2010) Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 123:397\u2013404","journal-title":"Breast Cancer Res Treat"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2021.12.023","article-title":"Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma","volume":"185","author":"Risom T","year":"2022","unstructured":"Risom T et al (2022) Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell 185:299\u2013310e18","journal-title":"Cell"},{"key":"ref18","first-page":"768","article-title":"Transcriptomic Properties of HER2\u2009+\u2009Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells","volume":"10","author":"Agahozo MC","year":"2021","unstructured":"Agahozo MC et al (2021) Transcriptomic Properties of HER2\u2009+\u2009Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. Biology (Basel) 10:768","journal-title":"Biology (Basel)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1158\/1541-7786.MCR-20-0949","article-title":"Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System","volume":"19","author":"Trinh A","year":"2021","unstructured":"Trinh A et al (2021) Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System. Mol Cancer Res 19:623\u2013635","journal-title":"Mol Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-15-0506","article-title":"A Molecular Portrait of High-Grade Ductal Carcinoma In Situ","volume":"75","author":"Abba MC","year":"2015","unstructured":"Abba MC et al (2015) A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. Cancer Res 75:3980\u20133990","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.celrep.2016.06.051","article-title":"Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer","volume":"16","author":"Lesurf R","year":"2016","unstructured":"Lesurf R et al (2016) Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. Cell Rep 16:1166\u20131179","journal-title":"Cell Rep"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir IL","year":"2011","unstructured":"Wapnir IL et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478\u2013488","journal-title":"J Natl Cancer Inst"},{"key":"ref23","article-title":"Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study","volume":"383","author":"Schmitz RSJM","year":"2023","unstructured":"Schmitz RSJM et al (2023) Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study. BMJ 383, e076022","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.759154","article-title":"TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer","volume":"9","author":"Zhang Z","year":"2021","unstructured":"Zhang Z, Hao R, Guo Q, Zhang S, Wang X (2021) TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer. Front Cell Dev Biology 9","journal-title":"Front Cell Dev Biology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1101\/060012","article-title":"Fast gene set enrichment analysis","volume":"060012","author":"Gennady","year":"2021","unstructured":"Gennady, Korotkevich et al (2021) Fast gene set enrichment analysis. bioRxiv 060012. 10.1101\/060012","journal-title":"bioRxiv"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/modpathol.2015.75","article-title":"Copy number analysis of ductal carcinoma in situ with and without recurrence","volume":"28","author":"Gorringe KL","year":"2015","unstructured":"Gorringe KL et al (2015) Copy number analysis of ductal carcinoma in situ with and without recurrence. Mod Pathol 28:1174\u20131184","journal-title":"Mod Pathol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tig.2023.02.009","article-title":"ATRX, a guardian of chromatin","volume":"39","author":"Aguilera P","year":"2023","unstructured":"Aguilera P, L\u00f3pez-Contreras AJ (2023) ATRX, a guardian of chromatin. Trends Genet 39:505\u2013519","journal-title":"Trends Genet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1101\/gad.292516.116","article-title":"ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair","volume":"31","author":"Leung JWC","year":"2017","unstructured":"Leung JWC et al (2017) ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. Genes Dev 31:260\u2013274","journal-title":"Genes Dev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13073-019-0684-0","article-title":"Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response","volume":"11","author":"Mardis ER","year":"2019","unstructured":"Mardis ER (2019) Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. Genome Med 11:71","journal-title":"Genome Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41416-022-01888-2","article-title":"Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk","volume":"127","author":"Almekinders MM","year":"2022","unstructured":"Almekinders MM et al (2022) Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. Br J Cancer 127:1201\u20131213","journal-title":"Br J Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdw623","article-title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","volume":"28","author":"Pruneri G","year":"2017","unstructured":"Pruneri G et al (2017) The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol 28:321\u2013328","journal-title":"Ann Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41379-019-0331-8","article-title":"Ductal carcinoma in situ of the breast: immune cell composition according to subtype","volume":"33","author":"Agahozo MC","year":"2020","unstructured":"Agahozo MC et al (2020) Ductal carcinoma in situ of the breast: immune cell composition according to subtype. Mod Pathol 33:196\u2013205","journal-title":"Mod Pathol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41416-020-0797-7","article-title":"The prognostic significance of immune microenvironment in breast ductal carcinoma in situ","volume":"122","author":"Toss MS","year":"2020","unstructured":"Toss MS et al (2020) The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. Br J Cancer 122:1496\u20131506","journal-title":"Br J Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","article-title":"Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features","volume":"23","author":"Hendry S","year":"2017","unstructured":"Hendry S et al (2017) Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features. Clin Cancer Res 23:5210\u20135217","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40425-019-0621-1","article-title":"Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma","volume":"7","author":"Ghatalia P","year":"2019","unstructured":"Ghatalia P et al (2019) Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer 7:139","journal-title":"J Immunother Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"680287","DOI":"10.3389\/fonc.2021.680287","article-title":"Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer","volume":"11","author":"Wang Q","year":"2021","unstructured":"Wang Q et al (2021) Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer. Front Oncol 11:680287","journal-title":"Front Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"CT003","DOI":"10.1158\/1538-7445.AM2019-CT003","article-title":"Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL","volume":"79","author":"Campbell MJ","year":"2019","unstructured":"Campbell MJ et al (2019) Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL. Cancer Res 79:CT003","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41523-021-00267-z","article-title":"Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection","volume":"7","author":"Glencer AC","year":"2021","unstructured":"Glencer AC et al (2021) Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. NPJ Breast Cancer 7:59","journal-title":"NPJ Breast Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study","volume":"158","author":"Doebar SC","year":"2016","unstructured":"Doebar SC et al (2016) Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Res Treat 158:179\u2013187","journal-title":"Breast Cancer Res Treat"},{"key":"ref40","unstructured":"mRNA-2752 with or without a PD1 Inhibitor in Treating Patients with High Grade Ductal Breast Carcinoma In Situ - NCI. https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCI-2017-01320 (2016)"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"PR07","DOI":"10.1158\/1538-7445.ADVBC23-PR07","article-title":"Abstract PR07: Intratumoral injection of mRNA-2752 and anti-PD-1 results in rapid regression of HER2 positive and or Hormone Receptor Negative DCIS: Phase 1 study results","volume":"84","author":"Esserman LJ","year":"2024","unstructured":"Esserman LJ et al (2024) Abstract PR07: Intratumoral injection of mRNA-2752 and anti-PD-1 results in rapid regression of HER2 positive and or Hormone Receptor Negative DCIS: Phase 1 study results. Cancer Res 84:PR07","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0192623315587593","article-title":"Introduction of Zinc-salt Fixation for Effective Detection of Immune Cell-related Markers by Immunohistochemistry","volume":"43","author":"Mori H","year":"2015","unstructured":"Mori H et al (2015) Introduction of Zinc-salt Fixation for Effective Detection of Immune Cell-related Markers by Immunohistochemistry. Toxicol Pathol 43:883\u2013889","journal-title":"Toxicol Pathol"},{"key":"ref43","author":"Baddeley A","year":"2015","unstructured":"Baddeley A, Rubak E, Turner R (2015) Spatial Point Patterns: Methodology and Applications with R. (Chapman & Hall\/CRC"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/282436","article-title":"Measurement of \u2018Overlap\u2019 in Comparative Ecological Studies","volume":"100","author":"Horn HS","year":"1966","unstructured":"Horn HS (1966) Measurement of \u2018Overlap\u2019 in Comparative Ecological Studies. Am Nat 100:419\u2013424","journal-title":"Am Nat"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF00344966","article-title":"Similarity indices, sample size and diversity","volume":"50","author":"Wolda H","year":"1981","unstructured":"Wolda H (1981) Similarity indices, sample size and diversity. Oecologia 50:296\u2013302","journal-title":"Oecologia"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1176935118782880","DOI":"10.1177\/1176935118782880","article-title":"A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms","volume":"17","author":"Barua S","year":"2018","unstructured":"Barua S et al (2018) A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. Cancer Inf 17:1176935118782880","journal-title":"Cancer Inf"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"15095","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens JL","year":"2017","unstructured":"Carstens JL et al (2017) Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 8:15095","journal-title":"Nat Commun"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo NA","year":"2019","unstructured":"Giraldo NA et al (2019) The clinical role of the TME in solid cancer. Br J Cancer 120:45\u201353","journal-title":"Br J Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson MD","year":"2010","unstructured":"Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26:1572\u20131573","journal-title":"Bioinformatics"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-021-00365-y","article-title":"The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ","volume":"8","author":"Nachmanson D","year":"2022","unstructured":"Nachmanson D et al (2022) The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ. npj Breast Cancer 8:1\u201313","journal-title":"npj Breast Cancer"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4126092\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4126092\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T13:24:56Z","timestamp":1731936296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4126092\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":50,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4126092\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,5,9]]},"subtype":"preprint"}}